OP0268

APOPTOSIS OF SYNOVIAL FIBROBLASTS INDUCED BY P53-DERIVED HYBRID PEPTIDES THROUGH DISSOCIATING THE BINDING OF P73 WITH IASPP TO INCREASE PUMA AND BAX EXPRESSION

C.-R. Wang¹, S.-Y. Chen¹, A.-L. Shiau², C.-L. Wu³. ¹Internal Medicine, National Cheng Kung University Hospital; ²Microbiology and Immunology; ³Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan, -

Background: In rheumatoid arthritis (RA) synovial fibroblasts (SFs), mutant p53 can lead to transformation-like features resistant to the apoptosis induction.¹ Deficiency in p53-mediated suppression by its dominant-negative counterpart is observed in human cancers with activating p73 as a therapeutic strategy in such patients.² A p53-derived hybrid peptide 37 amino acid (37AA) can inhibit the p73 binding with inhibitory apoptosis stimulating protein of p53 (IASPP), thus activating the downstream apoptosis signalling pathway in tumour cells.³

Objectives: We hypothesised that p73 is involved in the RA pathogenesis, and examined whether p53-derived hybrid peptides can activate p73 to induce apoptosis of SFs by using adenoviral vectors encoding 37AA (Ad37AA) to transduce SFs *in vitro* and inject collagen-induced arthritis (CIA) joints *in vivo*.

Methods: Mononuclear cells (MNCs) from RA patients before and after receiving the adalimumab therapy were examined for iASPP expression by real-time RT-PCR. Synovial tissues and SFs from RA patients and CIA rats were subjected to immunohistochemical and immunofluorescent staining and real-time RT-PCR for the p73 and iASPP expression. SFs transduced with Ad37AA, were subjected to TUNEL assay for apoptotic status and real-time RT-PCR for the expression of downstream apoptosis signalling molecule PUMA and Bax. SFs were transduced with lentiviral vectors-encoding short hairpin p73 RNA to produce p73-silenced SF transfectants. Therapeutic effects of Ad37AA injection were evaluated on CIA joints. Immunohistochemical staining and TUNEL assay were used to analyse synovial cadherin-11/PUMA/IL-6 expression and apoptotic cells, respectively.

Results: There were reduced iASPP levels by targeting TNF in RA MNCs, and increased p73 with co-localised iASPP expression in synovial lining layers and SFs from RA patients and CIA rats. Enhanced cell apoptosis, increased PUMA and Bax expression and lower iASPP-associated p73 levels were identified in Ad37AA-transduced SFs, and silencing p73 abrogated the increased PUMA and Bax expression. Articular indexes and histologic scores were reduced in Ad37AA-injected joints with decreased SF densities, increased apoptotic cells, higher PUMA expression and lower IL-6 levels.

Conclusions: These results demonstrate that injecting p53-derived hybrid peptides can induce apoptosis of SFs through the activation of p73 in the rheumatoid joint, suggesting that strengthening the p73-dependent apoptotic mechanism is a potential therapeutic strategy in RA patients.

REFERENCES:

- [1] Bell HS, et al. J Clin Invest 2007;117:1008–18.
- [2] Bottini N, et al. Nat Rev Rheumatol 2013;9:24–33.
- [3] Lozano G, et al. editor. The p53 protein: from cell regulation to cancer. Cold Spring Harbor Laboratory Press 2016;69–94.

Acknowledgements: We thank Dr. Kevin M. Ryan (Cancer Research UK Beatson Institute, Glasgow, UK) for providing pShuttleCMV-37AA adenoviral plasmids, and Drs. Ming-Fei Liu and I-Ming Jou (National Cheng Kung University Hospital) for providing synovial specimens from arthritis patients.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.1900

OP0269

ACTIVATION OF MERTK+CD206+ SUBPOPULATION OF HUMAN SYNOVIAL TISSUE-RESIDENT MACROPHAGES LIMITS INFLAMMATORY RESPONSE

S.R. Finlay¹, S. Alivernini², A. Elmesari¹, B. Toluoso³, L. Perticca³, C. Di Mario³, A. Capacci³, A. Filer⁴, G. Ferraccioli³, I. McInnes¹, E. Gremese³, M. Kurowska-Stolarska¹. ¹Institute of Infection, Immunity and Inflammation, Glasgow, UK; ²Institute of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Italy; ³Institute of Rheumatology, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy; ⁴Institute of Infection, Inflammation and Ageing, Birmingham, UK

Background: Current therapies have transformed the management of rheumatoid arthritis. However, there are still a substantial proportion of patients who do not respond to treatments, and among those who respond, only small proportion achieve disease remission. We showed previously that human synovial tissue macrophages (STMs) are a heterogeneous population; and a sub-population of CD206⁺MertK⁺ positive STMs predominates in RA patients in sustained remission, in contrast to patients with active RA. Their surface receptors, e.g. MerTK, and distinct transcriptome suggest that they may play a pivotal role in re-enforcing joint homeostasis during remission.¹ Thus, we hypothesise that activation of

CD206⁺MertK⁺ human synovial tissue macrophages contribute to the resolution of inflammation.

Objectives: We aimed to investigate whether activation of MerTK in STM sub-population promotes an anti-inflammatory environment in the synovium.

Methods: Using flow cytometric techniques and with a specific antibody panel design,¹ STMs from digested RA synovial biopsies (n=36) were phenotyped and/or harvested. Patients' group included 28 patients with active disease and 8 patients in remission (DAS28 ESR <2.6 and power doppler negative). After excluding all other cell types, macrophages were gated based on the expression of CD64 and CD11b (CD45^{pos}CD64^{pos}CD11b^{pos}HLA-DR^{pos}).¹ Two distinct sub-populations: CD206⁺MertK⁺ and CD206⁺MertK⁻ were sorted and cultured on a collagen coated 96-well plate at 1000 cells per well in the presence of with LPS (10 ng/ml)±Gas6, a MerTK ligand (200 ng/ml), for 24 hour. TNF production was measured with a high sensitivity ELISA.

Results: As previously shown,¹ RA patients in sustained remission have a majority of CD206⁺MertK⁺ STMs whilst patients with active RA show an increased number of CD206⁺MertK⁻ macrophages. The percentage of CD206⁺MertK⁺ macrophages negatively correlated with the disease activity score. Stimulation of FACS-Aria sorted CD206⁺MertK⁺ and CD206⁺MertK⁻ macrophages with TLR4 ligand induced TNF production. However, activation of MerTK pathway by Gas6 inhibited LPS-induced TNF production by CD206⁺MertK⁺ subpopulation.

Conclusions: CD206⁺MERTK⁺ macrophages, which predominate in RA patients in remission, have Gas6-mediated negative feedback mechanism limiting TNF production. Thus, Gas6/MerTK pathway in synovial tissue macrophages could drive the resolution of inflammation and synovial tissue homeostasis. Further functional and transcriptomics studies will reveal the therapeutic potential of CD206⁺MERTK⁺ macrophages.

REFERENCE:

- [1] Elmesari A, et al. Synovial tissue of RA patients in remission contains a unique population of regulatory macrophages. Annals of the Rheumatic Diseases 2017;76(Suppl2):138–139.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7265

OP0270

IGA ANTI-CCP ANTIBODIES ARE DETECTABLE IN THE SALIVA BUT NOT SPUTUM OF INDIVIDUALS AT-RISK OF DEVELOPING RHEUMATOID ARTHRITIS

K. Mankia¹, P. Pentony¹, L. Hunt¹, Y. El-Sherbiny², L. Duquenne¹, D. Corscadden², T. Do³, J. Meade³, D. Devine³, P. Emery¹. ¹Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine and NIHR Leeds Biomedical Research Centre; ²Rheumatology, Leeds Institute of Rheumatic and Musculoskeletal Medicine; ³Oral Microbiology, University of Leeds, Leeds, UK

Background: Recent evidence suggests the initiation of rheumatoid arthritis (RA) – related autoimmunity may occur by local citrullination at the oral mucosa and lungs. IgA antibodies are the hallmark of mucosal immunity; the majority of saliva IgA antibodies are locally produced whereas IgG antibodies are largely serum derived.¹ Furthermore, IgA anti-CCP antibodies have recently been described in the sputum of at-risk individuals.² The relative importance of the oral and lung mucosa in disease initiation is, however, unclear and the prevalence of saliva and sputum anti-CCP antibodies in the same at-risk individuals has not been reported.

Objectives: To investigate the prevalence of IgA anti-CCP antibodies in the saliva and sputum of seropositive individuals at risk of developing RA.

Methods: Anti-CCP positive individuals with no evidence of clinical synovitis (CCP+), anti-CCP positive RA patients (RA) and healthy controls (HC) matched for age and smoking status were recruited. Unstimulated saliva and serum samples were collected. Induced sputum samples were obtained using 7% saline via ultrasonic nebuliser (UltraNeb 3000 DA, Devilbiss, Germany). Sputum was mixed with phosphate buffered saline, mechanically disrupted and centrifuged to obtain supernatant. IgA and IgG anti-CCP antibodies (anti-CCP2, immunocap assay, Phadia) were measured in all saliva, sputum and serum samples. IgA and saliva/sputum IgG anti-CCP titres exceeding the 95th centile in HC were considered positive.

Results: 55 CCP+, 40 RA and 32 HC were recruited and had saliva and serum collected. 24 CCP+, 14 RA and 22 HC had sputum and serum collected. Of these, 23 CCP + and 7 RA patients provided simultaneous saliva, sputum and serum samples. 8/55 (15%) CCP + and 10/40 (25%) RA patients had positive saliva IgA anti-CCP levels compared with 1/31 (3%) HC. 23/54 (43%) CCP + and 21/48 (44%) RA patients had positive serum IgA anti-CCP levels compared with 1/32 (3%) HC (table 1). Of note, 7/18 (39%) patients with a positive saliva IgA anti-CCP test had a negative serum IgA anti-CCP test, suggesting localised production and accumulation of IgA anti-CCP antibodies rather than transfer from the serum. Only 1/24 CCP+ (4%) and 1/14 (7%) RA patients had positive sputum IgA anti-